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ABSTRACT: Objective: The objective of this study
was to develop valid prognostic models to predict mor-
tality, dependency, and “death or dependency” for use
in newly diagnosed Parkinson’s disease (PD).
Methods: The models were developed in the Parkin-
sonism Incidence in North-East Scotland study (UK,
198 patients) and validated in the ParkWest study (Nor-
way, 192 patients), cohorts that attempted to identify
and follow-up all new PD cases in the study area.
Dependency was defined using the Schwab & England
scale. We selected variables measured at time of diag-
nosis to include in the models. Internal validation and
external validation were performed by calculating C-
statistics (discrimination) and plotting observed versus
predicted risk in quantiles of predicted risk (calibration).
Results: Older age, male sex, increased severity of
axial features, and Charlson comorbidity index were
independent prognostic factors in the mortality model.
Increasing age, higher smoking history, increased sever-
ity of axial features, and lower MMSE score were inde-
pendent predictors in the models of dependency and
“death or dependency.” Each model had very good
internal calibration and very good or good discrimina-
tion (internal and external C-statistics for the models
were 0.73–0.75 and 0.68–0.78, respectively). Although
each model clearly separated patients into groups
according to risk, they tended to overestimate risk in
ParkWest. The models were recalibrated to the baseline
risk in the ParkWest study and then calibrated well in
this cohort.
Conclusions: We have developed prognostic models for
predicting medium-term risk of important clinical out-
comes in newly diagnosed PD. These models have validity
for use for stratification of randomization, confounder
adjustment, and case-mix correction, but they are inade-
quate for individualized prognostication. VC 2017. The
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Parkinson’s disease (PD) is a progressive disabling
disorder with higher mortality, disability, and demen-
tia than in controls.1,2 Being able to predict outcome
has many benefits, including individualized risk predic-
tion with improved information for patients, stratify-
ing or personalizing treatments according to
prognosis, improving design of clinical trials (eg, selec-
tion of participants, stratifying randomisation, or
adjustment for covariates), and adjusting for case-mix
when comparing different cohorts.3,4 It is important
that appropriate methods are used to develop prognos-
tic models, including a representative patient sample
and adequate external validation to demonstrate that
the model can be used in settings other than those in
which it was developed.3,4
Only one externally validated prognostic model has
been published for use in PD, but it is limited to pre-
dictions at a single timepoint (at 5 years) and uses a
single composite outcome.5 No prognostic models
have been published for specific outcomes in PD. We
therefore aimed to (1) develop prognostic models for
predicting 3 important outcomes over time in PD, that
is, mortality, dependency (needing help with basic
activities of daily living such as walking, dressing, toi-
leting), and the composite outcome of “death or
dependency” (which may be a useful simple clinical
measure of disease progression)6 and (2) to validate
these models in an international cohort. We have pre-
viously published data on individual predictors of
dependency and “death or dependency” in PD,7 but
this paper extends this work significantly by combin-
ing prognostic factors to develop and validate predic-
tive models for these outcomes and mortality.
Materials and Methods
We developed the prognostic models in the Parkin-
sonism Incidence in North-East Scotland (PINE) study
and performed external validation in the ParkWest
study in prospective, population-based incident
cohorts of PD (ie, which attempted to recruit and
follow-up all new PD cases in the specified time period
and area).
PINE Study (Development Cohort)
The PINE study was recruited during the following
2 incidence periods: an 18-month pilot phase in area
with population of 148,600 beginning November
2002 and the 36-month main study phase in popula-
tion of 317,357 people beginning April 2006.8-10
Patients were recruited using multiple, overlapping
strategies for case ascertainment, including writing to
general practitioners and hospital specialists asking
them to refer suspected cases, hand-searching neurol-
ogy/geriatrics referral letters, and electronic searching
of general practice and hospital discharge databases.
All those referred or identified through the searches
and who did not have a previous diagnosis of a par-
kinsonian disorder were invited to be assessed by a
neurologist with a special interest in movement disor-
ders (or supervised trainee). Those with parkinsonism
(defined as 2 or more of rest tremor, bradykinesia,
rigidity, or unexplained postural instability) were
invited to consent to long-term annual follow-up.
Consenting patients were reviewed annually with a
range of clinical assessments. Only those diagnosed
with idiopathic PD (guided by the UK PD Society
Brain Bank criteria)11 were included in this analysis.
ParkWest Study (Validation Cohort)
The ParkWest study sought to recruit all new PD
cases over 22 months from November 1, 2004, in 4
Norwegian counties comprising a population of
1,052,075.12 Similar to the PINE study, multiple,
overlapping strategies were used for case ascertain-
ment, including hand-searching referral letters, notifi-
cation of general practitioners and relevant hospital
specialists asking them to refer suspected cases, and
electronic searching of hospital databases and general
practitioners’ electronic medical records systems. All
new cases were invited to consent to follow-up with
twice-yearly assessment, including a range of clinical
assessments. PD diagnoses were made using the UK
PD Society Brain Bank criteria11 and the Gelb
criteria.13
Both studies were approved by appropriate ethics
committees (Multi-centre Research Ethics Committee
for Scotland, Edinburgh, UK, University of Bergen,
Bergen, Norway) and were conducted with the
informed consent of the patients involved.
Outcome Definition
Data on mortality were derived from notifications
by relatives/general practitioners plus surveillance by
the UK national death registers in the PINE study.
Functional dependency was measured by the Schwab
& England scale14 at follow-up visits and defined
using a cut-off of< 80% (80%5 completely indepen-
dent in most chores; 70%5 not completely indepen-
dent). The word chores was consistently interpreted as
basic activities of daily living (walking, personal
hygiene, dressing, toileting, feeding) by both study
teams. The Schwab & England scale has been partly
validated for use in PD as a measure of activities of
daily living,15-18 but its validity as a dichotomous
measure of dependency/independency has not been
established. Nevertheless, it does have face validity for
this purpose.
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Predictor Variables
We selected potential baseline predictors (ie, mea-
sured at diagnosis) to include in the model based on
previously reported associations,1,19 a previous
analysis of the measures of motor impairment with
best predictive value in the PINE study (in which
measures of axial severity were better predictors of
long-term outcomes than other measures of motor
function, including the postural-instability-gait-difficul-
ties/tremor-dominant classification),20 and clinical
knowledge. We limited the number of candidate pre-
dictors to avoid overfitting.21 We included age in the
models irrespective of statistical significance because,
on the basis of previous studies and clinical knowl-
edge, it strongly predicts many outcomes in PD. The
other candidate baseline variables were selected using
a backward stepwise selection process (see Model
Development): sex, pack years of smoking history,
Charlson comorbidity score,22 severity of bradykinesia
(sum of bradykinesia items from UPDRS [part III]
motor score), severity of axial features (sum of speech,
facial expression, face tremor, neck rigidity, arising
from chair, posture, gait, and postural instability items
from the UPDRS [part III] motor score), mini-mental
state examination (MMSE) score, and Hoehn & Yahr
stage. We previously compared the Charlson comor-
bidity score with 2 other scales and found it was more
reliable and had better predictive validity.23 There
were no missing data for predictor variables in either
study. Treatment-related variables were not included
to allow the models to be used at time of diagnosis
(ie, before treatment initiation) and in trials of de
novo treatment in PD.
Model Development
We developed 3 models to predict time to all-cause
mortality, time to dependency, and time to “death or
dependency.” We used Weibull proportional hazards
parametric survival modelling to allow direct estima-
tion of the baseline hazard function (the hazard func-
tion when centred covariates are set to 0), for ease of
out-of-sample prediction and for straightforward vali-
dation. We investigated other parametric distributions
of the baseline hazard, but none provided better fit
adjusted for complexity (assessed by the Bayesian infor-
mation criterion). Univariable analysis was performed
with each candidate predictor in turn, and then those
variables with association with the outcome of interest
(P< .2) were included in a backward stepwise regres-
sion model. A probability cut-off of .1 was used for
removal of variables from the model (other than age).
We checked whether the proportional odds or probit
scale fitted better than the proportional hazards scale,
but they did not. Functional form was tested by assess-
ing whether a 2-power fractional polynomial (ie, non-
linear terms) provided better fit.24 The influence of
individual observations on the models was assessed by
calculating the likelihood displacement.25 Because the
effect of baseline Charlson score on mortality varied
with time from the baseline assessment, an interaction
between Charlson score and 2 discrete periods of time
was added to the model (with approximately equal
numbers of deaths in each time period), resulting in sig-
nificantly improved fit (P5 .001). The significance of
interactions between age and other variables in the
model were assessed, but other interactions were not
tested because of limited power. Shrinkage was not
applied during prognostic modelling development as
the shrinkage factors were all >0.85.26
For the dependency model, patients who were depen-
dent at time of diagnosis were excluded and patients
who died or were lost to follow-up prior to becoming
dependent were censored at the time they were last
seen. We assumed that censoring because of death was
independent of dependency because most deaths in
those who were not previously known to be dependent
were not a result of PD and therefore unlikely to be
related to dependency. Patients remaining alive and
independent were censored at the time of their last visit
(or up until January 19, 2015 for surviving patients in
the PINE study). Two patients were excluded from the
development of the mortality model and 1 from the
dependency model because of unusual outlying values
together with high influence on the model.
Model Validation
We assessed validation by measuring discrimination
(the ability of a model to distinguish different risks
between individuals) and calibration (the degree of
agreement between observed event probability and
predicted event probability in groups of patients
defined by the prognostic index [xb]). Discrimination
was measured using the C-statistic, the proportion of
all possible pairs of observations in the dataset cor-
rectly ranked in terms of risk.27 Calibration was
assessed by plotting observed versus predicted survival
probabilities in 4 quantiles of predicted risk derived
from the models (ie, the prognostic index [xb]). First,
apparent discrimination and calibration was assessed,
that is, the direct performance of the models in the
PINE dataset in which they were created. Second, (so-
called) optimism-adjusted estimates of discrimination
in the PINE dataset were assessed using 500 boot-
strapped samples for each model.3,28 Third, the mod-
els developed in the PINE study were externally
validated by measuring their discrimination and
assessing their calibration in the ParkWest study.3,28
Model Recalibration
The models were recalibrated to account for a dif-
ferent baseline risk in the ParkWest study.29 This was
done by iterating the constant and shape parameter of
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the model so that the curve of mean predicted survival
probabilities for all patients in the ParkWest study
was a close fit to the observed Kaplan-Meier survival
probabilities (leaving the other parameter estimates
unchanged). The calibration plots were repeated using
the new constant and shape parameter to derive the
predicted values.
All statistical analyses were performed with Stata
version 12.1 (StataCorp LP, College Station, Texas).
Appropriate reporting guidelines have been
followed.30
Results
Supplementary Figure 1 shows recruitment to the
PINE and ParkWest studies. Consent to follow-up was
higher in the PINE study than in the ParkWest study
(94% vs 81%). A total of 198 patients with PD in
PINE and 192 patients with PD in ParkWest were
included in the analyses of mortality. Of the patients,
22 (11%) were excluded from analyses of dependency
in the PINE study and 30 in the ParkWest study
because they were already dependent at baseline
(16%). The patients in the PINE study were older
(mean age at diagnosis 72.5 vs 67.9), had shorter
median symptoms duration at baseline assessment (13
vs 20 months), higher smoking history, slightly higher
disease impairment and disease stage, and more
comorbidities (Table 1). Follow-up data were avail-
able for between 6 and 12 years from diagnosis in the
PINE study and between 6 and 8 years from diagnosis
in the ParkWest study.
Mortality
Mortality was higher in the PINE study than in the
ParkWest study (see Fig. 1A). We developed 2 models
predicting mortality, with and without the Charlson
comorbidity index, to enable use in settings where
comorbidity data is not available. Age, sex, and sever-
ity of axial features were included in both models
(Table 2). The model increased mortality with increas-
ing comorbidity burden in the first 4 years of follow-
up and a nonsignificant decrease in mortality with
increasing baseline Charlson score after 4 years
follow-up. Apparent discrimination and calibration
were very good (C-statistics 0.75 and 0.73 for model
with and without Charlson score, respectively; see cal-
ibration plot in Fig. 2A). Calibration plots for the
model without Charlson score are not shown, but are
almost identical. Both models discriminated better in
the external cohort than internally (C-statistics 0.76
TABLE 1. Baseline characteristics
Baseline variable
PINE,
N5 198
ParkWest,
N5192
Mean age in years at diagnosis (SD) 72.5 (10.4) 67.9 (9.3)
Number male (%) 119 (60) 117 (61)
Median symptom duration
in months (IQR)
13 (9-24) 20.0 (13.6-36.8)
Mean H&Y stage (SD) 2.3 (0.8) 1.9 (0.6)
Mean UPDRS motor score (SD) 25.1 (11.6) 23.5 (11.2)
Mean MMSE (SD) 28.1 (2.3) 27.8 (2.5)
Median Charlson score (IQR) 1 (0-2) 0 (0-1)
Median pack years of smoking
history (IQR)
0 (0-15) 8 (3-20)
IQR, interquartile range; PINE, Parkinsonism Incidence in North-East Scot-
land; SD, standard deviation.
FIG. 1. Plots of survival in the Parkinsonism Incidence in North-East
Scotland (PINE) and ParkWest studies. Plots of Kaplan-Meier probabil-
ity of (A) survival, (B) remaining independent (with deaths censored),
and (C) remaining alive and independent. Colored bands represent
95% confidence bands for the Kaplan-Meier survival probabilities. Ver-
tical marks represent censored observations. [Color figure can be
viewed at wileyonlinelibrary.com]
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and 0.78 for models with and without comorbidity
burden). However, although the calibration plot in the
ParkWest study showed good separation into groups
according to prognostic risk, the model tended to
overestimate risk of death except in the highest-risk
quantile (Fig. 2B). Using the recalibrated model, cali-
bration was very good (Fig. 3A).
Dependency
The probabilities of developing sustained depen-
dency over time were higher in the PINE study than in
the ParkWest study (Fig. 1B). Median time until
dependency was 5.5 years in the PINE study, but was
not reached in the ParkWest study. The model of
dependency developed in PINE included age, smoking
history, severity of axial features, and MMSE score
(Table 2). This model had relatively high apparent dis-
crimination (C-statistic 0.77) and very good calibra-
tion (Fig. 2C). Discriminative performance was also
very good in the validation cohort (C-statistic 0.75),
and although the calibration plots showed clear sepa-
ration by prognostic risk, there was systematic overes-
timation of risk of dependency in the validation
cohort (Fig. 2D). However, the recalibration plots
show much better calibration (Fig. 3B).
Death or Dependency
The risk of becoming “dead or dependent” was sub-
stantially higher in the PINE study than in the ParkW-
est study during most of the follow-up period (see Fig.
1C). The model of “death or dependency” developed
in PINE included the same variables as in the model
of dependency (Table 2). This model had good appar-
ent discrimination (C-statistic 0.74) and very good cal-
ibration (Fig. 2E). The model discriminated slightly
better in the ParkWest study (C-statistic 0.76). The
calibration plots showed clear separation by prognos-
tic risk, but there was systematic overestimation of
risk of “death or dependency” in the validation cohort
(Fig. 2F). The recalibrated model showed much
improved calibration (Fig. 3C).
For each model, assumptions were satisfied, linear
form was appropriate for interval variables, and there
was no evidence for interactions between age and
other variables. Supplementary Appendix 1 contains a
risk prediction calculator.
Discussion
These 3 prognostic models combine clinical features
at the time of diagnosis to predict important clinical
TABLE 2. Prognostic models
C-statistic (95% CI) – model discrimination
Internal (PINE)
Outcome Baseline prognostic factor
Hazard ratio (95%
confidence interval) Apparent
Optimism
corrected
External
(ParkWest)
All-cause mortality Age (10-year increase) 2.02 (1.51-2.71) 0.75 (0.70-0.80) 0.73 0.76 (0.68-0.85)
Male sex 1.78 (1.13-2.82)
Axial severity (5-point increase) 1.33 (1.08-1.66)
Charlson score (effect in first
4 years of follow-up)
1.31 (1.12-1.52)
Charlson score (effect after first 4 years) 0.83 (0.63-1.08)
Shape parameter 2.28 (1.90-2.74)
Constant 22.66 (23.09 to 2.23)
All-cause mortality (alternative
model excluding Charlson score)
Age (10-year increase) 2.12 (1.58-2.84) 0.73 (0.68-0.78) 0.71 0.78 (0.70-0.86)
Male sex 1.85 (1.17-2.91)
Axial severity (5-point increase) 1.41 (1.13-1.76)
Shape parameter 1.92 (1.61-2.28)
Constant 22.38 (22.77 to 2.00)
Functional dependency Age (10-year increase) 2.15 (1.61-2.86) 0.77 (0.72-0.82) 0.74 0.68 (0.61-0.75)
Smoking history (10-pack-year increase) 1.15 (1.05-1.27)
Axial severity (5-point increase) 1.74 (1.28-2.35)
MMSE score 0.86 (0.77-0.96)
Shape parameter 1.85 (1.56-2.18)
Constant 1.15 (0.05-28.1)
Death or dependency Age (10-year increase) 1.91 (1.50-2.44) 0.74 (0.69-0.79) 0.73 0.68 (0.62-0.75)
Smoking history (10-pack-year increase) 1.16 (1.07-1.26)
Axial severity (5-point increase) 1.56 (1.18-2.05)
MMSE score 0.86 (0.78-0.95)
Shape parameter 1.66 (1.43-1.92)
Constant 1.89 (0.11-32.8)
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outcomes in PD. They performed well in the PINE
cohort and when tested in the ParkWest cohort, they
had very good discrimination. Although there was
good separation into prognostic groups, there was a
systematic overestimation of risk in the patients in the
ParkWest study. We developed recalibrated models
that had good discrimination and calibration in the
Norwegian cohort.
These models are novel. Although many previous
studies have studied prognostic factors for mortality
and dependency in PD,1,19 and another study has
developed, but not externally validated, a prognostic
model for several outcomes including mortality,31 we
are unaware of any externally validated prognostic
model that can be used to calculate risk of specific
outcomes in PD. One recent study has published a
prognostic model developed in the Netherlands, and
validated in England, which combined 3 variables
(age, severity of axial features, and verbal fluency) to
predict a composite outcome (postural instability,
dementia, or death) at 5 years.5 Although this model
discriminated well (C-statistic 0.77 in the development
cohort and 0.85 in the validation cohort) and cali-
brated well, its use is limited to predictions at a single
timepoint and the components of the composite out-
come are not equal in severity. Our models have the
distinct advantages of predicting risk at multiple time-
points and of predicting specific outcomes.
FIG. 2. Internal and external calibration plots. Plots of model calibration showing the observed and predicted probabilities of outcome in quantiles
of predicted risk of survival in the Parkinsonism Incidence in North-East Scotland (PINE) study (A) and in the ParkWest study (B), of remaining inde-
pendent in the PINE study (C) and in the ParkWest study (D), and of remaining alive and independent in the PINE study (E) and in the ParkWest
study (F). The dashed lines indicate the probabilities predicted by the model, and the solid lines indicate the Kaplan-Meier survival function. [Color
figure can be viewed at wileyonlinelibrary.com]
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We do not here discuss particular prognostic factors
for dependency outcomes as we have done so previ-
ously.7 The finding that comorbidity was associated
with mortality but not the dependency outcomes may
be because many deaths, particularly early deaths,
were related to comorbid disease, whereas most dis-
ability was related to PD itself. The interaction
between comorbidity burden and time suggests that
baseline comorbidity is more important for early mor-
tality than for later mortality (given survival beyond
year 4).
This study has 3 principal strengths. The first lies in
the study designs, which both aimed to reduce selec-
tion bias by attempting to include all patients in the
population with newly diagnosed PD. However,
because PD is predominantly a disease of the elderly,
there were relatively few young-onset cases studied
(8.5%<55 at diagnosis). Although we are unaware of
evidence that the effects of the prognostic factors are
modified by age, the models should be used cautiously
in young-onset patient groups until they have under-
gone further validation in these groups.
The second main strength is the international exter-
nal validation of the models. The key threat to model
validity is overfitting as the model may fit too closely
the idiosyncrasies of the development dataset resulting
in overoptimistic estimates of model performance.3
Demonstrating that the model discriminates well in
another cohort provides direct evidence of its general-
izability to other settings and utility for certain appli-
cations. The third strength is that the models were
developed following recommendations for prognostic
studies4 using appropriate statistical methods.
An important limitation of this study relates to sam-
ple size. Although with about 100 deaths in the devel-
opment cohort about 10 predictors can be studied
without excessive overfitting,21 this limited selection
of candidate predictors and the investigation of poten-
tial interactions in the models. Therefore further work
in larger studies or combining studies could result in
better models for individualized risk prediction.
A second important limitation is poor calibration of
the models in the external cohort, which is probably
mainly attributable to the higher overall risk of mor-
tality and dependency in the PINE study. This must be
related to factors which were not included (and there-
fore adjusted for) in the models. Differences in mortal-
ity are most likely explained by differences in non-PD-
related mortality as it is unlikely the pathogenesis of
PD is fundamentally different between the 2 countries
and the burden of the diseases that most commonly
lead to death (cardiovascular disease, respiratory dis-
ease, and malignancy) is higher in the United Kingdom
than in Norway,32 which is reflected in the higher
mortality rates in the United Kingdom than in Nor-
way.33 Although there are no comparative population
data on dependency available, the comorbidity rate
was higher in the PINE study than in the ParkWest
study, which may have led to higher dependency risk
in the PINE study. Other possible explanations for
these differences include the older average age of
PINE participants and the lower consent rate in the
ParkWest cohort if frailer patients were less likely to
consent.
Because we have demonstrated the external validity
of these models in terms of discrimination, we antici-
pate that these models will have several uses as
research tools that separate patients into groups
according to prognostic risk. These include in clinical
trials design (eg, selection of participants for inclusion
based on baseline predicted prognosis, stratification of
randomization, and adjustment of analyses), adjust-
ment for confounding in observational studies, and
adjustment for case-mix (eg, in comparing cohorts
from different studies, countries, hospitals).3 These
models combine simple and easy-to-collect variables
that can easily be gathered in the clinic or in a
research context.
FIG. 3. Recalibrated model calibration plots. Plots of model calibration
showing the observed and predicted probabilities of outcome in quan-
tiles of predicted risk in the models recalibrated for the baseline risk in
the ParkWest study: (A) survival, (B) dependency, and (C) death or
dependency. The dashed lines indicate the probabilities predicted by
the model and the solid lines indicate the Kaplan-Meier survival func-
tion. [Color figure can be viewed at wileyonlinelibrary.com]
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Similarly, these models could also be used in clinical
practice for stratification of treatment according to
prognostic risk. Although there is no definite indica-
tion for this at present, this may be useful if disease
modifying treatments with potentially serious side
effects become available for PD. For example, they
could be used to select people with the worst progno-
sis to try such treatments. However, these models are
only a starting point; before these models can be used
for individualized or personalized medicine, we need
(1) further validation; (2) improved prediction, for
example, adding biomarkers such as genetic or imag-
ing factors; (3) simple implementation for use in clini-
cal practice; and (4) evaluation of benefit versus harm,
ideally in randomized trials34,35 because the use of
models to guide treatments may cause harm as well as
benefit (eg, from false negative or false positive predic-
tions). It will be important to develop flexible dynamic
models that use accumulating data over time (such as
disease progression, motor or nonmotor complica-
tions) to predict later outcomes but clearly those data
are not available at diagnosis, and therefore models
that use baseline data only are relevant for use in early
disease.
Although prognostic models that discriminate well
can be useful for research purposes and for treatment
stratification even if they do not calibrate well, indi-
vidualized risk prediction requires better precision
than these uses and must calibrate well in the settings
in which they are used. Although the original models
worked well in North-East Scotland, it was necessary
to recalibrate to the ParkWest population in Western
Norway. Therefore, the models should be recalibrated
before use for individualized risk prediction in other
geographical areas. This can be easily done if esti-
mates of survival rate or progression to dependency
are available.
In conclusion, we have developed and validated
prognostic models to predict important outcomes in
PD that use predictors that can be easily measured in
the clinic setting. We have demonstrated that these
models have sufficient validity to be used in a research
context, but that recalibration is required before use
in other geographical areas for individualized risk pre-
diction. Further work includes (1) developing more-
accurate models with individual-patient data meta-
analyses of representative studies; (2) further valida-
tion in a young-onset cohort; (3) further simplification
for use in case-mix correction (eg, to identify which
components of the axial features variable need to be
collected); (3) updating these models to include bio-
marker data, for example, genetic, imaging, or bio-
chemical data; (4) updating baseline risk in the models
in the future if, for example, disease-modifying treat-
ments are introduced, which would alter the natural
history of the disease; and (5) evaluation of their use
in clinical management of individual patients. The use
of these models in randomized controlled trials to
stratify randomization by baseline prognosis would
allow further validation by comparing participants’
predicted and actual outcome.
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